

Patient Name	: Mr MR.DUMMY	Sample Collected	: Apr 26, 2024, 01:00 PM.
DOB/Age/Gender	: 23 Y/Male	Report Date	: May 09, 2024,01:12 PM.
Patient ID / UHID	: 8052461/RCL7248747	Barcode No	: ZC665922
Referred By	: Dr. X	Report Status	: Final Report
Sample Type	: Serum		

Inhibin B

Inhibin B (Serum,EIA)	4.49	pg/mL	21.0-53.0
---------------------------------	------	-------	-----------

Interpretation:

- Inhibin values fluctuate during the menstrual cycle thus levels in premenopausal women should be interpreted with caution.
- Serum Inhibin levels should not be interpreted as absolute evidence of the presence or the absence of malignant disease. Results are to be used in conjunction with clinical evaluation of the patient and other diagnostic procedures

Note

- All result interpretation should be in conjunction with clinical evaluation of the patient and other diagnostic procedures.
- Elevation of Inhibin B after treatment is suggestive of residual, recurrent or progressive disease.

Comments

Inhibins are protein hormones secreted by Granulosa cells of the ovary in females and Sertoli cells of the testes in males. Inhibin B is primarily produced by small developing follicles and fluctuates during the menstrual cycle. It increases early in the follicular phase to reach a peak corresponding with mid-follicular phase decline in FSH levels and decreases in late follicular phase. Inhibin B levels are elevated in 89-100% patients with Granulosa cell tumors and 55-60% patients with Epithelial ovarian tumors. Normal Inhibin B level does not rule out a Mucinous or Granulosa cell ovarian tumor.

Clinical Use

- As an aid in the diagnosis & monitoring of Granulosa cell tumors and Mucinous epithelial ovarian tumors
- To assess ovarian reserve, inhibin B level in the postmenopausal range is suggestive of diminished or depleted ovarian reserve.
- As an adjunct to FSH testing during Infertility evaluation.

*** End Of Report ***

Disclaimer: Method given in report are only indicative and can be changed depending upon type of machine and kit available at time of testing.

Not all tests at all locations are under NABL scope. Availability of tests under NABL scope varies from lab to lab.



Dr. Dummy



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
Processing Lab :-

📞 928-909-0609

✉ ccsupport@redcliffelabs.com

🌐 www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.

DISCLAIMER

This is a sample report provided for demonstration purposes only and does not represent an actual patient report. Test results, reference ranges, methodologies, instrumentation, and report formats may vary depending on the laboratory performing the test. The format and representation shown are indicative of reports generated by the National Reference Laboratory of Redcliffe Labs, Noida. This sample report should not be used for medical interpretation, diagnosis, or treatment decisions.